fashion -WSS

fashion

author：leisure time 2025-08-23 21:55:54 - browse：154

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： CDC wastewater surveillance dashboard to track bird flu hotspots

WSS

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Steward Health Care files for bankruptcy

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

focus

fashion

hotspot

The high cost of giving birth even with insurance

Why do we get seasonal allergies?

Peter Hotez and the public health issue of online harassment

Medical experts exlpore how to eliminate bias in clinical algorithms

ChatGPT in medicine: STAT answers readers' burning questions

Sanofi strikes deal with Novavax, boosting the vaccine maker

How one medical school became remarkably diverse

Illumina to lay off 10% of research and development team

Moonlake's readout produced a cash windfall. Risks remain

Telehealth startups turn to complex chronic diseases

entertainment

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Steward Health Care files for bankruptcy

Medical experts exlpore how to eliminate bias in clinical algorithms

Synthetic human embryos? Researchers say term is overblown

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Sanofi strikes deal with Novavax, boosting the vaccine maker

hotspot

knowledge

focus

Wikipedia